A Few Hepatitis C Market Developments Worldwide In H2, 2017}

A FEW HEPATITIS C MARKET DEVELOPMENTS WORLDWIDE IN H2, 2017

by

JohnPattersonHepatitis C Virus (HCV) is a small virus that causes acute and chronic infections of the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipments. HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug. During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). FEW HEPATITIS C MARKET DEVELOPMENTS WORLDWIDE- Mayvret drug (glecaprevir and pibrentasvir) of Abbvie gets FDA and EU approval- HCV infections in California increased 55% and 37% among men and women respectively between 2007 and 2015- Kite Pharma anticipates approval of its CAR-T treatment- Gilead Sciences to buy Kite Pharma for $12 billion- Ascletis gains Chinese marketing rights to nucleotide polymerase inhibitor MIV-802 (hepatitis C candidate of Medivir)- Hepatitis C Virus NS5A observed to Target NAP1L1 to Control the Innate Cellular Response- Curexa Pharmacy starts Dispensing Vosevi (sofosbuvir, velpatasvir, and voxilaprevir) administered orally for the Treatment of Chronic Hepatitis C- July 28th observed as World Hepatitis Day globally- Next frontier of chronic HCV therapies are expected to involve pan-genotypic regimens with short durations- Merck’s Zepatier estimated to generate revenues of around $800 million in H1 2017- Generic hepatitis C drugs produce similar cure rates to those reported in clinical trials according to Dr James Freeman, Australia- Egyptian hepatitis C treatment drug sales dropped by 68% in H1 2017 to EGP58.8m from EGP 185m in H1 2016 according to IMSFor more recent developments in Global Hepatitis C drug pipeline markets, please visit https://www.reportmarkets.com/20038-PharmaPoint–Hepatitis-C-Virus–HCV–Therapeutics—Global-Drug-Forecast-and-Market-Analysis-to-2025The report also provides- Favourable R&D strategies to remain competitive in future hepatitis C marketplace- Epidemiological Forecast of HCV to 2025- Impact of pan-genotypic DAA regimens on global hepatitis C industry- Enrolment dynamics and their response based on changing treatment rates and growth in cure ratesHighlights Key Questions Answered – Based on interviews with key opinion leaders (KOLs), The Author has identified key unmet needs in the hepatitis C marketplace. – What will be the effect of recent and upcoming approval of pan-genotypic DAA regimens – How will patient populations develop with changing treatment rates and high cure rates – What research and development (R&D) strategies will companies leverage to compete in the future hepatitis C marketplace – Which patient population(s) are most likely to be targeted by upcoming pan-genotypic DAA treatment algorithms Key Findings – The Author estimates that drug sales for hepatitis C in 2015 were approximately $21.7 billion across the 9MM. The global hepatitis C market is expected to experience a steady decline during the forecast period resulting in total sales of $17.5 billion by 2025.

Contact:

ReportmarketsMail:JohnPattersonPhone:sales@reportmarkets.com+19285924068

Article Source:

eArticlesOnline.com}